Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease

详细信息    查看全文

• 作者：Naomi Yoshida^a ; ^{qu_up_fl_o_wer@yahoo.co.jp} ; Masaki Okamoto^a ; ^{okamoto_masaki@med.kurume-u.ac.jp} ; Shinjiro Kaieda^a ; ^{kaieda@med.kurume-u.ac.jp} ; Kiminori Fujimoto^b ; ^{kimichan@med.kurume-u.ac.jp} ; Tomohiro Ebata^b ; ^{ebata_tomohiro@med.kurume-u.ac.jp} ; Morihiro Tajiri^a ; ^{motajiri@med.kurume-u.ac.jp} ; Masayuki Nakamura^a ; ^{nakamura@med.kurume-u.ac.jp} ; Masaki Tominaga^a ; ^{tominaga_masaki@med.kurume-u.ac.jp} ; Daisuke Wakasugi^a ; ^{wakasugi_daisuke@kurume-u.ac.jp} ; Tomotaka Kawayama^a ; ^{kawayama_tomotaka@med.kurume-u.ac.jp} ; Masataka Kuwana^c ; ^{kuwanam@nms.ac.jp} ; Tsuneyo Mimori^d ; ^{mimorit@kuhp.kyoto-u.ac.jp} ; Hiroaki Ida^a ; ^{ida@med.kurume-u.ac.jp} ; Tomoaki Hoshino^a ; ^{hoshino@med.kurume-u.ac.jp}
• 关键词：ILD ; Interstitial lung disease ; PM/DM ; polymyositis/dermatomyositis ; Anti-ARS Ab ; Anti-aminoacyl-transfer RNA synthetase antibody ; ASS ; antisynthetase syndrome ; Anti-MDA5 Ab ; melanoma differentiation-associated gene 5 antibody ; CsA ; cyclosporin A ; IVCY ; intravenous cyclophosphamide
• 刊名：Respiratory Investigation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：55
• 期：1
• 页码：24-32
• 全文大小：835 K
• 卷排序：55

文摘

We attempted to clarify whether the presence of anti-aminoacyl-transfer RNA synthetase antibody (anti-ARS Ab) or anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 Ab) is associated with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD).MethodsWe retrospectively investigated 22 patients with PM/DM-ILD (10 positive for anti-ARS Ab and nine positive for anti-MDA5 Ab) for whom antibody analysis of conserved serum was possible. We assessed mortality in the first three months as the therapeutic response in the acute phase and compared changes in clinical data for up to one year considered as the chronic phase. We classified the clinical changes over the year into three groups: Improvement (increased % vital capacity [%VC] or diffusing capacity of the lung for carbon monoxide [%DLCO]≥10 or 15%), deterioration (decreased %VC or %DLCO≥10 or 15%), and no change (remainder of the changes). The extent of abnormality demonstrated by high-resolution computed tomography (HRCT) was scored.ResultsPositivity for anti-MDA5 Ab, but not for anti-ARS Ab, was associated with mortality in the first 3 months. Evaluation of the therapeutic response in the first year showed that positivity for the anti-ARS Ab, but not for the anti-MDA5 Ab, was associated with an improvement in %DLCO and a decline in the serum KL-6 levels. Positivity for the anti-ARS Ab or negativity for anti-MDA5 Ab was associated with a greater decrease in bronchial dilatation as seen by HRCT.ConclusionsAnti-ARS and anti-MDA5 Abs are associated with the therapeutic response of PM/DM-ILD.